ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC) by prior local and systemic treatment

Podobne zapisy

• 346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
  od: Christian Poehlein, i wsp.
  Wydane: (2020-11-01)
• Systemic Triple Therapy in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
  od: Tomislav Omrčen
  Wydane: (2022-01-01)
• Efficacy and safety of apalutamide with high-volume mHSPC: Real-world experience from three cases
  od: Jingqi Jiang, i wsp.
  Wydane: (2023-09-01)
• Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
  od: Kenrick Ng, i wsp.
  Wydane: (2020-06-01)
• Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT
  od: Dagmar Grob, i wsp.
  Wydane: (2024-04-01)